{"nct_id":"NCT01605396","title":"A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)","status":"COMPLETED","status_verified_date":"2019-03","start_date":"2012-07-04","start_date_type":"ACTUAL","primary_completion_date":"2014-02-19","primary_completion_date_type":"ACTUAL","completion_date":"2018-03-15","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["MRK"]}